Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07827027) titled 'Evaluation of the Bioequivalence of RAY1225 Injection in Healthy Participants' on Sept. 14.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).

Primary Sponsor: Guangdong Raynovent Biotech Co., Ltd

Condition: Basic Science

Intervention: Drug: RAY1225

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: September 21, 2026

Target Sample Size: 68

To know more, visit https://clinicaltrials.gov/study/NCT07827027

Published by HT Digital Content Services with permission fr...